Intercept Pharmaceuticals, Inc.
(NASDAQ : ICPT)

( )
ICPT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corp. Plc
23.83%20.941.7%$162.94m
VRXValeant Pharmaceuticals International, Inc.
1.85%27.0114.1%$158.93m
BHCBausch Health Cos., Inc.
1.85%27.010.0%$119.66m
GWPHGW Pharmaceuticals Plc
-3.38%109.406.2%$81.05m
MDCOThe Medicines Co.
-3.58%53.3920.2%$78.63m
JAZZJazz Pharmaceuticals Plc
1.11%132.332.3%$69.12m
SAGESAGE Therapeutics, Inc.
-1.93%141.558.6%$52.41m
PRGOPerrigo Co. Plc
-1.67%48.286.8%$46.00m
ENDPEndo International Plc
0.61%4.148.8%$44.46m
HZNPHorizon Therapeutics Plc
0.73%30.236.6%$40.27m
UTHRUnited Therapeutics Corp.
-1.53%89.5714.3%$39.81m
ICPTIntercept Pharmaceuticals, Inc.
1.29%83.0216.9%$39.56m
ICLRICON plc
0.73%147.244.1%$37.50m
CTLTCatalent, Inc.
-0.74%49.482.4%$32.17m
AERIAerie Pharmaceuticals, Inc.
-0.89%18.886.8%$26.95m

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.